JP2011529691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529691A5 JP2011529691A5 JP2011521359A JP2011521359A JP2011529691A5 JP 2011529691 A5 JP2011529691 A5 JP 2011529691A5 JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011521359 A JP2011521359 A JP 2011521359A JP 2011529691 A5 JP2011529691 A5 JP 2011529691A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- dna
- gene
- tumor
- template
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004414 DNA Proteins 0.000 claims description 61
- 239000012634 fragment Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 239000000523 sample Substances 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 230000035772 mutation Effects 0.000 claims description 28
- 239000011324 bead Substances 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 10
- 239000000839 emulsion Substances 0.000 claims description 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 10
- 238000002271 resection Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 108091093088 Amplicon Proteins 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 7
- 108700028369 Alleles Proteins 0.000 claims description 6
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 238000012163 sequencing technique Methods 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 239000012736 aqueous medium Substances 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 108010090804 Streptavidin Proteins 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000007762 w/o emulsion Substances 0.000 claims description 3
- 239000012491 analyte Substances 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 230000001351 cycling effect Effects 0.000 claims description 2
- 238000000295 emission spectrum Methods 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims 3
- 239000002853 nucleic acid probe Substances 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 1
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims 1
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 238000009534 blood test Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000002563 stool test Methods 0.000 claims 1
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 22
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 22
- 238000001356 surgical procedure Methods 0.000 description 12
- 230000002550 fecal effect Effects 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002980 postoperative effect Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000012752 Hepatectomy Methods 0.000 description 3
- 238000001325 log-rank test Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000011521 systemic chemotherapy Methods 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000012321 colectomy Methods 0.000 description 2
- 201000010897 colon adenocarcinoma Diseases 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 102200006532 rs112445441 Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000001599 sigmoid colon Anatomy 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 238000001347 McNemar's test Methods 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000005162 left hepatic lobe Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000005163 right hepatic lobe Anatomy 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 238000013538 segmental resection Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8517508P | 2008-07-31 | 2008-07-31 | |
| US61/085,175 | 2008-07-31 | ||
| US12/512,585 | 2009-07-30 | ||
| US12/512,585 US20100041048A1 (en) | 2008-07-31 | 2009-07-30 | Circulating Mutant DNA to Assess Tumor Dynamics |
| PCT/US2009/052436 WO2010014920A1 (en) | 2008-07-31 | 2009-07-31 | Circulating mutant dna to assess tumor dynamics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015231649A Division JP2016104010A (ja) | 2008-07-31 | 2015-11-27 | 腫瘍動態を評価するための循環変異型ｄｎａ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529691A JP2011529691A (ja) | 2011-12-15 |
| JP2011529691A5 true JP2011529691A5 (enExample) | 2012-08-30 |
Family
ID=41610753
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521359A Pending JP2011529691A (ja) | 2008-07-31 | 2009-07-31 | 腫瘍動態を評価するための循環変異型ｄｎａ |
| JP2015231649A Pending JP2016104010A (ja) | 2008-07-31 | 2015-11-27 | 腫瘍動態を評価するための循環変異型ｄｎａ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015231649A Pending JP2016104010A (ja) | 2008-07-31 | 2015-11-27 | 腫瘍動態を評価するための循環変異型ｄｎａ |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US20100041048A1 (enExample) |
| EP (1) | EP2315849B1 (enExample) |
| JP (2) | JP2011529691A (enExample) |
| CA (1) | CA2732623C (enExample) |
| WO (1) | WO2010014920A1 (enExample) |
Families Citing this family (120)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005009324D1 (de) | 2005-04-06 | 2008-10-09 | Maurice Stroun | Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf |
| US11111544B2 (en) | 2005-07-29 | 2021-09-07 | Natera, Inc. | System and method for cleaning noisy genetic data and determining chromosome copy number |
| US9424392B2 (en) | 2005-11-26 | 2016-08-23 | Natera, Inc. | System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| JP2012511927A (ja) | 2008-12-17 | 2012-05-31 | ライフ テクノロジーズ コーポレーション | 対立遺伝子変種を検出するための方法、組成物、およびキット |
| EP3249053A1 (en) | 2009-03-27 | 2017-11-29 | Life Technologies Corporation | Methods, compositions, and kits for detecting allelic variants |
| EP2536854B1 (en) * | 2010-02-18 | 2017-07-19 | The Johns Hopkins University | Personalized tumor biomarkers |
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11332785B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11332793B2 (en) | 2010-05-18 | 2022-05-17 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11326208B2 (en) | 2010-05-18 | 2022-05-10 | Natera, Inc. | Methods for nested PCR amplification of cell-free DNA |
| US11339429B2 (en) | 2010-05-18 | 2022-05-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US11408031B2 (en) | 2010-05-18 | 2022-08-09 | Natera, Inc. | Methods for non-invasive prenatal paternity testing |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| CA3207599A1 (en) | 2010-05-18 | 2011-11-24 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| KR20130113447A (ko) | 2010-09-24 | 2013-10-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화 |
| SG190344A1 (en) | 2010-11-30 | 2013-06-28 | Univ Hong Kong Chinese | Detection of genetic or molecular aberrations associated with cancer |
| BR112013020220B1 (pt) | 2011-02-09 | 2020-03-17 | Natera, Inc. | Método para determinar o estado de ploidia de um cromossomo em um feto em gestação |
| DK3246416T3 (da) | 2011-04-15 | 2024-09-02 | Univ Johns Hopkins | Sikkert sekventeringssystem |
| JP2013081450A (ja) * | 2011-09-27 | 2013-05-09 | Arkray Inc | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用試薬キット |
| WO2013083810A1 (en) * | 2011-12-09 | 2013-06-13 | F. Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
| EP2814959B1 (en) * | 2012-02-17 | 2018-01-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for accurately identifying mutations |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| WO2014004726A1 (en) * | 2012-06-26 | 2014-01-03 | Caifu Chen | Methods, compositions and kits for the diagnosis, prognosis and monitoring of cancer |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| KR102393608B1 (ko) | 2012-09-04 | 2022-05-03 | 가던트 헬쓰, 인크. | 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법 |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| EP2912196B1 (en) | 2012-10-26 | 2018-08-08 | Sysmex Corporation | Emulsion systems for emulsion-based amplification of nucleic acid |
| ES2886507T5 (es) | 2012-10-29 | 2024-11-15 | Univ Johns Hopkins | Prueba de Papanicolaou para cánceres de ovario y de endometrio |
| EP2964781B1 (en) | 2013-03-08 | 2018-01-10 | Roche Diagnostics GmbH | Egfr mutation blood testing |
| US20140287417A1 (en) | 2013-03-08 | 2014-09-25 | Roche Molecular Systems, Inc. | EGFR Blood Monitoring |
| DK2970958T3 (en) | 2013-03-15 | 2018-02-19 | Lineage Biosciences Inc | METHODS FOR SEQUENCING THE IMMUN REPERTOIR |
| EP4253558B1 (en) | 2013-03-15 | 2025-07-02 | The Board of Trustees of the Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| US9116866B2 (en) | 2013-08-21 | 2015-08-25 | Seven Bridges Genomics Inc. | Methods and systems for detecting sequence variants |
| US9898575B2 (en) | 2013-08-21 | 2018-02-20 | Seven Bridges Genomics Inc. | Methods and systems for aligning sequences |
| WO2015058097A1 (en) | 2013-10-18 | 2015-04-23 | Seven Bridges Genomics Inc. | Methods and systems for identifying disease-induced mutations |
| US11049587B2 (en) | 2013-10-18 | 2021-06-29 | Seven Bridges Genomics Inc. | Methods and systems for aligning sequences in the presence of repeating elements |
| WO2015058095A1 (en) | 2013-10-18 | 2015-04-23 | Seven Bridges Genomics Inc. | Methods and systems for quantifying sequence alignment |
| WO2015058093A1 (en) | 2013-10-18 | 2015-04-23 | Seven Bridges Genomics Inc. | Methods and systems for genotyping genetic samples |
| CA2926722A1 (en) * | 2013-10-19 | 2015-04-23 | Trovagene, Inc. | Detecting mutations in disease over time |
| US9092402B2 (en) | 2013-10-21 | 2015-07-28 | Seven Bridges Genomics Inc. | Systems and methods for using paired-end data in directed acyclic structure |
| EP3378952B1 (en) | 2013-12-28 | 2020-02-05 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
| US9817944B2 (en) | 2014-02-11 | 2017-11-14 | Seven Bridges Genomics Inc. | Systems and methods for analyzing sequence data |
| US12492429B2 (en) | 2014-04-21 | 2025-12-09 | Natera, Inc. | Detecting mutations and ploidy in chromosomal segments |
| EP3134541B1 (en) | 2014-04-21 | 2020-08-19 | Natera, Inc. | Detecting copy number variations (cnv) of chromosomal segments in cancer |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| US20160002717A1 (en) * | 2014-07-02 | 2016-01-07 | Boreal Genomics, Inc. | Determining mutation burden in circulating cell-free nucleic acid and associated risk of disease |
| US20170211143A1 (en) | 2014-07-25 | 2017-07-27 | University Of Washington | Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same |
| US12391985B2 (en) | 2014-08-07 | 2025-08-19 | Pharmassist Ltd | Method of determining PIK3CA mutational status in a sample |
| PT3198026T (pt) * | 2014-08-07 | 2020-01-16 | Pharmassist Ltd | Método de determinação do estado mutacional de pik3ca numa amostra |
| EP3191628B1 (en) | 2014-09-12 | 2022-05-25 | The Board of Trustees of the Leland Stanford Junior University | Identification and use of circulating nucleic acids |
| JP6531312B2 (ja) * | 2014-10-17 | 2019-06-19 | 東洋鋼鈑株式会社 | Ｂｃｒ−ａｂｌ阻害剤耐性関連変異の検出方法及びこれを用いたｂｃｒ−ａｂｌ阻害剤耐性を予測するためのデータ取得方法 |
| EP4012715B1 (en) | 2015-02-10 | 2025-09-24 | The Chinese University Of Hong Kong | Detecting mutations for cancer screening and fetal analysis |
| WO2016141294A1 (en) | 2015-03-05 | 2016-09-09 | Seven Bridges Genomics Inc. | Systems and methods for genomic pattern analysis |
| CN104762399A (zh) * | 2015-04-17 | 2015-07-08 | 上海产业技术研究院 | 肿瘤循环dna kras突变检测方法 |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| KR101701618B1 (ko) | 2015-06-23 | 2017-02-13 | 국립암센터 | 전도성 고분자를 이용한 세포 유리 ｄｎａ 검출용 구조체 및 이의 용도 |
| WO2017014177A1 (ja) * | 2015-07-17 | 2017-01-26 | 凸版印刷株式会社 | 健康状態の評価方法及び抗がん剤に対する長期奏功性の予測方法 |
| WO2017027653A1 (en) | 2015-08-11 | 2017-02-16 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| US10793895B2 (en) | 2015-08-24 | 2020-10-06 | Seven Bridges Genomics Inc. | Systems and methods for epigenetic analysis |
| US10584380B2 (en) | 2015-09-01 | 2020-03-10 | Seven Bridges Genomics Inc. | Systems and methods for mitochondrial analysis |
| US10724110B2 (en) | 2015-09-01 | 2020-07-28 | Seven Bridges Genomics Inc. | Systems and methods for analyzing viral nucleic acids |
| US11756655B2 (en) * | 2015-10-09 | 2023-09-12 | Guardant Health, Inc. | Population based treatment recommender using cell free DNA |
| US11347704B2 (en) | 2015-10-16 | 2022-05-31 | Seven Bridges Genomics Inc. | Biological graph or sequence serialization |
| EP3170903B1 (en) * | 2015-11-20 | 2019-09-18 | Qiagen GmbH | Method for processing a water-in-oil emulsion |
| JP2019507585A (ja) | 2015-12-17 | 2019-03-22 | ガーダント ヘルス， インコーポレイテッド | 無細胞ｄｎａの分析による腫瘍遺伝子コピー数を決定するための方法 |
| US20170199960A1 (en) | 2016-01-07 | 2017-07-13 | Seven Bridges Genomics Inc. | Systems and methods for adaptive local alignment for graph genomes |
| US10364468B2 (en) * | 2016-01-13 | 2019-07-30 | Seven Bridges Genomics Inc. | Systems and methods for analyzing circulating tumor DNA |
| JP6685138B2 (ja) | 2016-01-27 | 2020-04-22 | シスメックス株式会社 | 核酸増幅の精度管理方法、精度管理用試薬およびその試薬キット |
| US10262102B2 (en) | 2016-02-24 | 2019-04-16 | Seven Bridges Genomics Inc. | Systems and methods for genotyping with graph reference |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| US10790044B2 (en) | 2016-05-19 | 2020-09-29 | Seven Bridges Genomics Inc. | Systems and methods for sequence encoding, storage, and compression |
| US11289177B2 (en) | 2016-08-08 | 2022-03-29 | Seven Bridges Genomics, Inc. | Computer method and system of identifying genomic mutations using graph-based local assembly |
| US11250931B2 (en) | 2016-09-01 | 2022-02-15 | Seven Bridges Genomics Inc. | Systems and methods for detecting recombination |
| WO2018067517A1 (en) | 2016-10-04 | 2018-04-12 | Natera, Inc. | Methods for characterizing copy number variation using proximity-litigation sequencing |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| CN114774520B (zh) * | 2016-11-17 | 2025-09-05 | 阅尔基因技术（苏州）有限公司 | 检测肿瘤发展的系统和方法 |
| US10011870B2 (en) | 2016-12-07 | 2018-07-03 | Natera, Inc. | Compositions and methods for identifying nucleic acid molecules |
| MY197535A (en) | 2017-01-25 | 2023-06-21 | Univ Hong Kong Chinese | Diagnostic applications using nucleic acid fragments |
| WO2018138539A1 (en) * | 2017-01-25 | 2018-08-02 | Qiagen Gmbh | Method for processing a water-in-oil emulsion |
| JP6933907B2 (ja) | 2017-02-24 | 2021-09-08 | シスメックス株式会社 | 核酸増幅方法 |
| US10726110B2 (en) | 2017-03-01 | 2020-07-28 | Seven Bridges Genomics, Inc. | Watermarking for data security in bioinformatic sequence analysis |
| US11347844B2 (en) | 2017-03-01 | 2022-05-31 | Seven Bridges Genomics, Inc. | Data security in bioinformatic sequence analysis |
| WO2018183942A1 (en) | 2017-03-31 | 2018-10-04 | Grail, Inc. | Improved library preparation and use thereof for sequencing-based error correction and/or variant identification |
| US10527608B2 (en) | 2017-06-13 | 2020-01-07 | Genetics Research, Llc | Methods for rare event detection |
| US10081829B1 (en) | 2017-06-13 | 2018-09-25 | Genetics Research, Llc | Detection of targeted sequence regions |
| US10947599B2 (en) | 2017-06-13 | 2021-03-16 | Genetics Research, Llc | Tumor mutation burden |
| CA3069938A1 (en) | 2017-06-13 | 2018-12-20 | Genetics Research, Llc, D/B/A Zs Genetics, Inc. | Isolation of target nucleic acids |
| WO2018231967A2 (en) * | 2017-06-13 | 2018-12-20 | Genetics Research, Llc, D/B/A Zs Genetics, Inc. | Rare nucleic acid detection |
| US10636512B2 (en) | 2017-07-14 | 2020-04-28 | Cofactor Genomics, Inc. | Immuno-oncology applications using next generation sequencing |
| DK3658684T3 (da) | 2017-07-26 | 2023-10-09 | Univ Hong Kong Chinese | Forbedring af cancerscreening ved hjælp af cellefrie, virale nukleinsyrer |
| CN111868260B (zh) | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12046325B2 (en) | 2018-02-14 | 2024-07-23 | Seven Bridges Genomics Inc. | System and method for sequence identification in reassembly variant calling |
| WO2019161244A1 (en) | 2018-02-15 | 2019-08-22 | Natera, Inc. | Methods for isolating nucleic acids with size selection |
| CN111742058B (zh) * | 2018-02-21 | 2025-11-14 | 纽克莱克斯有限公司 | 用于确定从全血分离血浆的效率的方法和试剂盒 |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| JP6975350B2 (ja) * | 2018-05-03 | 2021-12-01 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 腫瘍突然変異量の測定のための代理マーカーおよび方法 |
| US11702697B2 (en) * | 2018-05-14 | 2023-07-18 | Roche Sequencing Solutions, Inc. | Quality testing of DNA samples |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| JP6544783B1 (ja) | 2018-07-31 | 2019-07-17 | 学校法人 岩手医科大学 | がんの診断のためのプローブ／プライマーライブラリー |
| EP3725894A1 (en) * | 2019-04-16 | 2020-10-21 | Blod Diagnostik GmbH | Apparatus and methods for nucleic acid target enrichment, suspension and quantification |
| WO2020247263A1 (en) | 2019-06-06 | 2020-12-10 | Natera, Inc. | Methods for detecting immune cell dna and monitoring immune system |
| US20220228221A1 (en) * | 2019-06-17 | 2022-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostics and Treatments Based Upon Molecular Characterization of Colorectal Cancer |
| JP2023508411A (ja) | 2019-12-23 | 2023-03-02 | バイオプセンス オサケユキチュア | 血液試料からセルフリー核酸を抽出するための方法、自動化システムおよびカートリッジ |
| CN115516108A (zh) | 2020-02-14 | 2022-12-23 | 约翰斯霍普金斯大学 | 评估核酸的方法和材料 |
| CN111575377B (zh) * | 2020-05-19 | 2024-02-23 | 邹畅 | 用于line-1的检测引物组及其应用 |
| WO2022031620A2 (en) * | 2020-08-01 | 2022-02-10 | Aigene | Methods for the rapid assessment of the efficacy of cancer therapy and related applications |
| US20220275450A1 (en) * | 2021-02-24 | 2022-09-01 | Michael J. Powell | Method for conducting early detection of colon cancer and/or of colon cancer precursor cells and for monitoring colon cancer recurrence |
| AU2022261868A1 (en) * | 2021-04-22 | 2023-10-26 | Natera, Inc. | Methods for determining velocity of tumor growth |
| WO2024203348A1 (ja) * | 2023-03-31 | 2024-10-03 | ソニーグループ株式会社 | 腫瘍の解析方法、腫瘍の解析システム、及び腫瘍の解析データ生成方法 |
| AU2024252845A1 (en) | 2023-04-06 | 2025-10-16 | Glaxosmithkline Intellectual Property (No.4) Limited | Methods for treating and monitoring cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6156504A (en) * | 1996-03-15 | 2000-12-05 | The Penn State Research Foundation | Detection of extracellular tumor-associated nucleic acid in blood plasma or serum using nucleic acid amplification assays |
| US20020120409A1 (en) * | 2000-05-19 | 2002-08-29 | Affymetrix, Inc. | Methods for gene expression analysis |
| US20030165940A1 (en) * | 2001-12-06 | 2003-09-04 | The Johns Hopkins University | Disease detection by digital protein truncation assays |
| GB0208089D0 (en) * | 2002-04-09 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Protein |
| US9109256B2 (en) | 2004-10-27 | 2015-08-18 | Esoterix Genetic Laboratories, Llc | Method for monitoring disease progression or recurrence |
| US20090280479A1 (en) * | 2005-05-27 | 2009-11-12 | John Wayne Cancer Institute | Use of free circulating dna for diagnosis, prognosis, and treatment of cancer funding |
| WO2007050465A2 (en) * | 2005-10-24 | 2007-05-03 | The Johns Hopkins University | Improved methods for beaming |
| EP2007423A2 (en) * | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| US20100041048A1 (en) * | 2008-07-31 | 2010-02-18 | The Johns Hopkins University | Circulating Mutant DNA to Assess Tumor Dynamics |
| US8517508B2 (en) | 2009-07-02 | 2013-08-27 | Fujifilm Dimatix, Inc. | Positioning jetting assemblies |
-
2009
- 2009-07-30 US US12/512,585 patent/US20100041048A1/en not_active Abandoned
- 2009-07-31 CA CA2732623A patent/CA2732623C/en active Active
- 2009-07-31 EP EP09803662.7A patent/EP2315849B1/en not_active Revoked
- 2009-07-31 WO PCT/US2009/052436 patent/WO2010014920A1/en not_active Ceased
- 2009-07-31 JP JP2011521359A patent/JP2011529691A/ja active Pending
-
2015
- 2015-11-27 JP JP2015231649A patent/JP2016104010A/ja active Pending
-
2019
- 2019-12-19 US US16/721,548 patent/US20200370123A1/en not_active Abandoned
-
2023
- 2023-01-23 US US18/100,301 patent/US20240002948A1/en not_active Abandoned
-
2024
- 2024-12-18 US US18/985,830 patent/US20250313901A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529691A5 (enExample) | ||
| US20250313901A1 (en) | Circulating mutant dna to assess tumor dynamics | |
| US11674183B2 (en) | Analytical methods for cell free nucleic acids and applications | |
| TWI532843B (zh) | 與癌症有關之基因或分子變異之檢測 | |
| US9109256B2 (en) | Method for monitoring disease progression or recurrence | |
| US20230366034A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| JP5486720B2 (ja) | 結腸直腸癌の予後のための遺伝子発現マーカー | |
| US20120028264A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| CN110964814B (zh) | 用于核酸序列变异检测的引物、组合物及方法 | |
| JP7665659B2 (ja) | 循環腫瘍核酸分子のマルチモーダル分析 | |
| JP6438119B2 (ja) | ホットスポット変異の迅速かつ高感度の検出のための方法 | |
| WO2019064063A1 (en) | BIOMARKERS FOR DETECTION OF COLORECTAL CANCER | |
| CN105431738A (zh) | 胃癌的预后预测模型的建立方法 | |
| JP2015107091A (ja) | 膵臓がんの検出キット及び検出方法 | |
| AU2004250246A1 (en) | Methods for disease screening | |
| EP3728630A1 (en) | Compositions and methods for diagnosing lung cancers using gene expression profiles | |
| JP5322471B2 (ja) | メチル化ｄｎａの解析方法及びプライマーセット | |
| TWI417546B (zh) | 肺腺癌預後之甲基化分子指標 | |
| JP2016189746A (ja) | プライマー対、プローブ、薬剤耐性ｃ型肝炎ウイルスの検出キット、薬剤耐性ｃ型肝炎ウイルスの検出方法およびｃ型肝炎の予後予測方法 | |
| JP2024534509A (ja) | ｃｆＲＮＡおよびｃｆＴＮＡの標的ＮＧＳシーケンシングのための組成物および方法 | |
| US20070248546A1 (en) | Clinical algorithm for excluding patients identified in virtual imaging | |
| WO2025109033A1 (en) | Method for identifying if a subject is at risk of developing lung cancer |